Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Distinct Mechanisms Underlying the Ex Vivo Expansion of Human Cord Blood Stem Cells with Different Strategies Currently Used for Allogeneic Transplantation

Luena Papa, PhD, Mansour Djedaini, BS, Christoph Schaniel, PhD, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 4470.

https://doi.org/10.1182/blood-2019-127040

Published: 2019

Journal Articles

Preliminary Phase 2 Results Demonstrate Engraftment with Minimal Neutropenia with MGTA-456, a CD34 + Expanded Cord Blood (CB) Product in Patients Transplanted for Inherited Metabolic Disorders (IMD)

Paul Orchard, MD, Glen D. Raffel, MD, Carolyn H Condon, MPH, Catherine A Monaghan, Demetra Vernet, Suzanne Tracey Sheirr, Jennifer Braun, RN BSN, Ryan Shanley, M.S, Troy C Lund, MD MS, PhD, Anthony E. Boitano, PhD, Michael P. Cooke, PhD, John C Davis, MD MPH, John E. Wagner, MD

Blood (2018) 132 (Supplement 1): 3467.

https://doi.org/10.1182/blood-2018-99-115102

Published: 2018

Journal Articles

MGTA-456, a First-in-Class Cell Therapy Produced from a Single Cord Blood Unit, Enables a Reduced Intensity Conditioning Regimen and Enhances Speed and Level of Human Microglia Engraftment in the Brains of NSG Mice

Kevin A. Goncalves, PhD, Shuping Li, PhD, Melissa L. Brooks, BS, Sharon L. Hyzy, MS, Anthony E. Boitano, PhD, Michael P. Cooke, PhD

Blood (2018) 132 (Supplement 1): 115.

https://doi.org/10.1182/blood-2018-99-118258

Published: 2018

Journal Articles

Mgta-456 Contains Large Numbers of Expanded Cord Blood (CB) CD34+CD90+ Hematopoietic Stem Cells (HSC) Which Confer All Engraftment Activity and Correlate with Accelerated Neutrophil Recovery after Myeloablative Conditioning in Patients with Hematologic Malignancy

Anthony E. Boitano, PhD, Michael P. Cooke, PhD, Kevin A. Goncalves, PhD, Darin Sumstad, MLS, John E. Wagner, MD

Blood (2018) 132 (Supplement 1): 2083.

https://doi.org/10.1182/blood-2018-99-114988

Published: 2018

Journal Articles

Aryl Hydrocarbon Receptor Antagonists Expand Adult Hematopoietic Stem Cells from Mobilized Peripheral Blood and Bone Marrow and Increase the Dose of CRISPR/Cas9 Gene-Edited NSG-Repopulating Cells

Megan D. Hoban, PhD, Kevin A. Goncalves, PhD, Jennifer L. Proctor, BS, Hillary L. Adams, MS, Sharon L. Hyzy, MS, Katia S. George, BA, Anthony E. Boitano, PhD, Michael P. Cooke, PhD

Blood (2017) 130 (Supplement 1): 3341.

https://doi.org/10.1182/blood.V130.Suppl_1.3341.3341

Published: 2017

Journal Articles

The Aryl Hydrocarbon Receptor Antagonist Stemregenin 1 Stimulates Expression of NK Cell Related Transcription Factors, Thereby It Facilitates Generation of Highly Functional NK Cells in Vitro

Mieke WH Roeven, MD, Jeanette Cany, PhD, Frans Maas, Arwa Kohela, Jansen Joop, PhD, Nicole MA Blijlevens, MD PhD, Nicolaas PM Schaap, MD PhD, Harry Dolstra, PhD

Blood (2014) 124 (21): 3833.

https://doi.org/10.1182/blood.V124.21.3833.3833

Published: 2014

Journal Articles

StemRegenin-1 (SR1) Expansion Culture Abrogates the Engraftment Barrier Associated with Umbilical Cord Blood Transplantation (UCBT)

John E Wagner, MD, Claudio Brunstein, MD, David McKenna, MD, Darin Sumstad, MT(ASCP), Suzanne Maahs, Mary Laughlin, MD, Michael S. Perry, DVM,PhD, Anthony E. Boitano, PhD, Michael P. Cooke, PhD, Conrad C. Bleul, MD

Blood (2014) 124 (21): 728.

https://doi.org/10.1182/blood.V124.21.728.728

Published: 2014

Journal Articles

Ex Vivo Generation Of Functional Plasmacytoid and Myeloid Dendritic Cells Is Strongly Promoted By The Aryl Hydrocarbon Receptor Antagonist Stemregenin 1

Soley Thordardottir, MSc, Hangalapura Basav N., PhD, Tim Hutten, MSc, Marta Cossu, MSc, Jan Spanholtz, PhD, Nicolaas PM Schaap, MD, PhD, Timothy Radstake, MD, PhD, Robbert van der Voort, PhD, Harry Dolstra, PhD

Blood (2013) 122 (21): 2025.

https://doi.org/10.1182/blood.V122.21.2025.2025

Published: 2013

Journal Articles

Novel Long-Term Co-Culture Approach Identifies Prognostically Important Heterogeneity Of Stem/Progenitor Cell Involvement In Human Acute Myeloid Leukemia

George S. Laszlo, PhD, Jack M. Lionberger, MD, PhD, Kimberly H. Harrington, BS, Chelsea J. Gudgeon, BS, Megan Othus, PhD, Frederick R. Appelbaum, MD, Irwin D. Bernstein, MD, Roland B. Walter, MD, PhD

Blood (2013) 122 (21): 1318.

https://doi.org/10.1182/blood.V122.21.1318.1318

Published: 2013

Journal Articles

Safety and Exploratory Efficacy Of Ex Vivo Expanded Umbilical Cord Blood (UCB) Hematopoietic Stem and Progenitor Cells (HSPC) Using Cytokines and Stem-Regenin 1 (SR1): Interim Results Of a Phase 1/2 Dose Escalation Clinical Study

John E. Wagner, MD, Claudio G Brunstein, MD, David McKenna, MD, Darin Sumstad, MT(ASCP), Suzanne Maahs, Anthony E. Boitano, PhD, Michael P. Cooke, PhD, Conrad C. Bleul, MD

Blood (2013) 122 (21): 698.

https://doi.org/10.1182/blood.V122.21.698.698

Published: 2013

Journal Articles

ZFN-Driven Gene Editing Prevents HLA-A Expression On Hematopoietic Stem Cells -Improving The Chance Of Finding An HLA-Matched Donor

Hiroki Torikai, Tiejuan Mi, Sonny O Ang, PhD, Loren Gragert, Martin Maiers, Sourindra Maiti, PHD, Kirsten Switzer, Helen Huls, BS, Andreas Reik, Michael C. Holmes, PhD, Philip D Gregory, PhD, Richard E Champlin, MD, Elizabeth J Shpall, MD, Laurence J N Cooper, MD, PhD

Blood (2013) 122 (21): 1655.

https://doi.org/10.1182/blood.V122.21.1655.1655

Published: 2013

NARROW

Distinct Mechanisms Underlying the Ex Vivo Expansion of Human Cord Blood Stem Cells with Different Strategies Currently Used for Allogeneic Transplantation

Preliminary Phase 2 Results Demonstrate Engraftment with Minimal Neutropenia with MGTA-456, a CD34 + Expanded Cord Blood (CB) Product in Patients Transplanted for Inherited Metabolic Disorders (IMD)

MGTA-456, a First-in-Class Cell Therapy Produced from a Single Cord Blood Unit, Enables a Reduced Intensity Conditioning Regimen and Enhances Speed and Level of Human Microglia Engraftment in the Brains of NSG Mice

Mgta-456 Contains Large Numbers of Expanded Cord Blood (CB) CD34+CD90+ Hematopoietic Stem Cells (HSC) Which Confer All Engraftment Activity and Correlate with Accelerated Neutrophil Recovery after Myeloablative Conditioning in Patients with Hematologic Malignancy

Aryl Hydrocarbon Receptor Antagonists Expand Adult Hematopoietic Stem Cells from Mobilized Peripheral Blood and Bone Marrow and Increase the Dose of CRISPR/Cas9 Gene-Edited NSG-Repopulating Cells

The Aryl Hydrocarbon Receptor Antagonist Stemregenin 1 Stimulates Expression of NK Cell Related Transcription Factors, Thereby It Facilitates Generation of Highly Functional NK Cells in Vitro

StemRegenin-1 (SR1) Expansion Culture Abrogates the Engraftment Barrier Associated with Umbilical Cord Blood Transplantation (UCBT)

Ex Vivo Generation Of Functional Plasmacytoid and Myeloid Dendritic Cells Is Strongly Promoted By The Aryl Hydrocarbon Receptor Antagonist Stemregenin 1

Novel Long-Term Co-Culture Approach Identifies Prognostically Important Heterogeneity Of Stem/Progenitor Cell Involvement In Human Acute Myeloid Leukemia

Safety and Exploratory Efficacy Of Ex Vivo Expanded Umbilical Cord Blood (UCB) Hematopoietic Stem and Progenitor Cells (HSPC) Using Cytokines and Stem-Regenin 1 (SR1): Interim Results Of a Phase 1/2 Dose Escalation Clinical Study

ZFN-Driven Gene Editing Prevents HLA-A Expression On Hematopoietic Stem Cells -Improving The Chance Of Finding An HLA-Matched Donor

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only